Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics.
Endogenous hypothermic response to hypoxia reduces brain injury: Implications for modeling hypoxic-ischemic encephalopathy and therapeutic hypothermia in neonatal mice.
Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care.
Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
A multi-biomarker follow-up study of patients with multiple sclerosis.
The Role of Biogenic Amines in the Regulation of Interaction between the Immune and Nervous Systems in Multiple Sclerosis.
Cortical gray and subcortical white matter associations in Parkinson's disease.
[A treatment of neuromyelitis optica (Devic's disease) during pregnancy].
Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.
Nuclear Protein Kinase CLK1 Uses A Nontraditional Docking Mechanism To Select Physiological Substrates.
Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis.
Regenerative Capacity of Macrophages for Remyelination.
The Impact of the Nurses' Health Study on Population Health: Prevention, Translation, and Control.
Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies.
Stroke induces specific alteration of T memory compartment controlling auto-reactive CNS antigen-specific T cell responses.
Coping with Multiple Sclerosis Scale: Reconsideration of the Factorial Structure.
Comprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial.
NG2-glia, More Than Progenitor Cells.
Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases.
Do coping strategies mediate the association between Type D personality and quality of life among people with multiple sclerosis?
IKKβ-mediated inflammatory myeloid cell activation exacerbates experimental autoimmune encephalomyelitis by potentiating Th1/Th17 cell activation and compromising blood brain barrier.
Clinical significance of Tim3-positive T cell subsets in patients with multiple sclerosis.
Default mode network changes in multiple sclerosis: a link between depression and cognitive impairment?
Pathological background of subcortical hyperintensities on diffusion-weighted images in a case of neuronal intranuclear inclusion disease.
Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis.
Pages
« first
‹ previous
…
779
780
781
782
783
784
785
786
787
…
next ›
last »